David Lodge (neuroscientist)

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
David Lodge
FRS FMedSci
Dr David Lodge FMedSci FRS.jpg
David Lodge at the Royal Society admissions day in London, July 2016
Alma materUniversity of Bristol (PhD, DSc)
AwardsDoctor of Science (2002)
Scientific career
Institutions
ThesisNeuropharmacological and physiological studies on central neurones in the rat (1974)
Doctoral advisorTim Biscoe
Other academic advisorsDavid Curtis
Websitewww.bris.ac.uk/synaptic/people/david-lodge/

David Lodge FRS[1] is a Research Fellow in the Department of Physiology and Pharmacology at the University of Bristol.[2][3]

Education[edit]

Lodge was awarded a Bachelor of Veterinary Science degree in 1963[where?] and worked in University of Bristol as a surgeon and anaesthetist, before doing postgraduate research with Tim J. Biscoe[4] on the neuropharmacology of amino acids, he was awarded his PhD in 1974.[1][5]

Research and career[edit]

During postdoctoral studies at the Australian National University with David Curtis, he helped establish the role of glutamate as a central neurotransmitter and characterised its actions between AMPA, N-Methyl-D-aspartic acid (NMDA) and kainate receptor subtypes. At the Royal Veterinary College, Lodge linked his interests in anaesthesia and glutamate receptors by making the key discovery that the dissociative anaesthetics, ketamine and phencyclidine,[6] selectively blocked NMDA receptors. He related NMDA receptor antagonism to psychotomimetic effects. This provided a basis for the glutamate hypothesis of schizophrenia and redirected pharmaceutical search for schizophrenia therapies. David was recruited as a director of Eli Lilly's neuroscience program, where he helped develop glutamate receptor approaches to brain diseases, resulting in clinical trials, e.g. for schizophrenia, some of which are ongoing. As of 2016, Lodge's research concerns the mechanism of action of new ‘legal highs’ and the consequences of spontaneous mutations in glutamate receptors.[1]

Awards and honours[edit]

Lodge was elected a Fellow of the Royal Society (FRS) in 2016[1] and a Fellow of the Academy of Medical Sciences.[when?] He was awarded a Doctor of Science degree from the University of Bristol in 2002.[7]

References[edit]

  1. ^ a b c d Anon (2016). "Dr David Lodge FMedSci FRS". London: Royal Society. Archived from the original on 2016-04-29. One or more of the preceding sentences incorporates text from the royalsociety.org website where:

    “All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” --"Royal Society Terms, conditions and policies". Archived from the original on September 25, 2015. Retrieved 2016-03-09.

  2. ^ David Lodge's publications indexed by the Scopus bibliographic database. (subscription required)
  3. ^ "Professor David Lodge, MRC Centre for Synaptic Plasticity". Bristol: bris.ac.uk. Archived from the original on 2016-05-21.
  4. ^ T. J. Biscoe, A. W. Duggan & D. Lodge (1972). "Effect of etorphine, morphine and diprenorphine on neurones of the cerebral cortex and spinal cord of the rat". British Journal of Pharmacology. 46 (2): 201–212. doi:10.1111/j.1476-5381.1972.tb06865.x. PMC 1666335. PMID 4405610.
  5. ^ Lodge, David (1974). Neuropharmacological and physiological studies on central neurones in the rat. proquest.com (PhD). University of Bristol.
  6. ^ Lodge, D; Mercier, M S (2015). "Ketamine and phencyclidine: the good, the bad and the unexpected". British Journal of Pharmacology. 172 (17): 4254–4276. doi:10.1111/bph.13222. PMC 4556466. PMID 26075331.
  7. ^ Lodge, David (2002). Material submitted in support of candidature for Doctor of Science. exlibrisgroup.com (DSc). University of Bristol. OCLC 931576764.